Translational efficacy of humanized exposures of cefepime, ertapenem, and levofloxacin against extended-spectrum-β-lactamase-producing Escherichia coli in a murine model of complicated urinary tract infection

Marguerite L. Monogue, David P. Nicolaua

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Validated animal models are required as bridging tools to assess the utility of novel therapies and potential microbiologic outcomes. Herein, we utilized uropathogenic extended-spectrum-β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in the neutropenic murine complicated urinary tract infection (cUTI) model with humanized exposures of cefepime, ertapenem, and levofloxacin to assess its translational value to human outcomes. Our data support the translational utility of this murine model to cUTI in humans as humanized exposures produced microbiologic outcomes consistent with the phenotypic profiles of the organisms.

Original languageEnglish (US)
Article numbere01329-17
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number11
DOIs
StatePublished - Nov 2017
Externally publishedYes

Fingerprint

Levofloxacin
Urinary Tract Infections
Escherichia coli
Animal Models
cefepime
ertapenem
Therapeutics

Keywords

  • Cefepime
  • Ertapenem
  • ESBL
  • Escherichia coli
  • Levofloxacin
  • Urinary tract infection

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

@article{9ae78f8ff825420d820f827192381b97,
title = "Translational efficacy of humanized exposures of cefepime, ertapenem, and levofloxacin against extended-spectrum-β-lactamase-producing Escherichia coli in a murine model of complicated urinary tract infection",
abstract = "Validated animal models are required as bridging tools to assess the utility of novel therapies and potential microbiologic outcomes. Herein, we utilized uropathogenic extended-spectrum-β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in the neutropenic murine complicated urinary tract infection (cUTI) model with humanized exposures of cefepime, ertapenem, and levofloxacin to assess its translational value to human outcomes. Our data support the translational utility of this murine model to cUTI in humans as humanized exposures produced microbiologic outcomes consistent with the phenotypic profiles of the organisms.",
keywords = "Cefepime, Ertapenem, ESBL, Escherichia coli, Levofloxacin, Urinary tract infection",
author = "Monogue, {Marguerite L.} and Nicolaua, {David P.}",
year = "2017",
month = "11",
doi = "10.1128/AAC.01329-17",
language = "English (US)",
volume = "61",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Translational efficacy of humanized exposures of cefepime, ertapenem, and levofloxacin against extended-spectrum-β-lactamase-producing Escherichia coli in a murine model of complicated urinary tract infection

AU - Monogue, Marguerite L.

AU - Nicolaua, David P.

PY - 2017/11

Y1 - 2017/11

N2 - Validated animal models are required as bridging tools to assess the utility of novel therapies and potential microbiologic outcomes. Herein, we utilized uropathogenic extended-spectrum-β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in the neutropenic murine complicated urinary tract infection (cUTI) model with humanized exposures of cefepime, ertapenem, and levofloxacin to assess its translational value to human outcomes. Our data support the translational utility of this murine model to cUTI in humans as humanized exposures produced microbiologic outcomes consistent with the phenotypic profiles of the organisms.

AB - Validated animal models are required as bridging tools to assess the utility of novel therapies and potential microbiologic outcomes. Herein, we utilized uropathogenic extended-spectrum-β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in the neutropenic murine complicated urinary tract infection (cUTI) model with humanized exposures of cefepime, ertapenem, and levofloxacin to assess its translational value to human outcomes. Our data support the translational utility of this murine model to cUTI in humans as humanized exposures produced microbiologic outcomes consistent with the phenotypic profiles of the organisms.

KW - Cefepime

KW - Ertapenem

KW - ESBL

KW - Escherichia coli

KW - Levofloxacin

KW - Urinary tract infection

UR - http://www.scopus.com/inward/record.url?scp=85032503606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032503606&partnerID=8YFLogxK

U2 - 10.1128/AAC.01329-17

DO - 10.1128/AAC.01329-17

M3 - Article

C2 - 28848015

AN - SCOPUS:85032503606

VL - 61

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

M1 - e01329-17

ER -